Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Potential Therapeutic Targets Including Amplifications of FGFR2.

Nicholas C. Turner(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Alex Pearson(Breast Cancer Now), Hugo M. Horlings, Marc J. van de Vijver(The Netherlands Cancer Institute), Alan Mackay(Institute of Cancer Research), A. Ashworth(London Health Sciences Centre), Rachel Sharpe(Guy's Hospital), Marieke van Kouwenhove(Amsterdam UMC Location University of Amsterdam), Felipe C. Geyer(Institute of Cancer Research), R. Natrajan(Institute of Cancer Research), Maryou Lambros(Institute of Cancer Research), Bas Kreike(The Netherlands Cancer Institute)
Cancer Research
December 1, 2009
10.1158/0008-5472.sabcs-09-3147
Cited by 1

Related Papers

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
The landscape of cancer genes and mutational processes in breast cancer
|Nature|2012|1.7k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k